Olenasufligene relduparvovec (LYSOGENE)

N/A

Report date: 2024/11/18 20:00:28

Base Information

Drug NameOlenasufligene relduparvovec (LYSOGENE)
Drug Alias NameOlenasufligene relduparvovec - LYSOGENEAAVrh10-hSGSHSAF-302SRP-9002AAVrh10-h.SGSH +[7] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVrh10 vector
Mechanisms of ActionGene transference
TargetsN-sulphoglucosamine sulphohydrolase
Therapy Area/IndicationsMucopolysaccharidosis III
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsGermany +[5] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLysogeneSarepta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSarepta Therapeutics IncLysogene
Active IndicationsN/A
Inactive IndicationsMucopolysaccharidosis III

Other Information

ATC CodeN/A
Related LinksN/A